$CTIX Company News Cellceutix Brilacidin IND effective,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$CTIX Company News

Cellceutix Brilacidin IND effective, Phase 2 to begin 9:31 a.m. Oct. 13, 2014 - Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 9:02 a.m. Sept. 25, 2014 - Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin 2:38 p.m. Sept. 21, 2014 - Seeking Alpha
10-K: CELLCEUTIX CORP 12:53 p.m. Sept. 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 2:06 a.m. Sept. 14, 2014 - Seeking Alpha
The Antibiotic Resistance Triple Threat 1:05 p.m. Sept. 4, 2014 - Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial 8:45 a.m. Aug. 19, 2014 - Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? 10:38 a.m. Aug. 14, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 9:15 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix 9:34 a.m. April 25, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 4:09 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin 9:31 a.m. Jan. 28, 2014 - Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward 3:17 p.m. Jan. 2, 2014 - Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014 9:06 a.m. Dec. 16, 2013 - Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference 5:38 a.m. Nov. 19, 2013 - Seeking Alpha
10-Q: CELLCEUTIX CORP 5:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP 3:01 p.m. Sept. 30, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP 1:18 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich 8:57 a.m. Nov. 15, 2011 - GuruFocus.com

Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders 6:00 a.m. Oct. 31, 2014 - Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin 10:52 a.m. Oct. 23, 2014 - Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 8:02 a.m. Oct. 13, 2014 - Marketwired
Cellceutix Provides Update to Shareholders 11:30 a.m. Sept. 24, 2014 - Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health 6:15 a.m. Sept. 19, 2014 - Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 2:01 p.m. Sept. 9, 2014 - Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference 10:17 a.m. Sept. 5, 2014 - Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting 6:01 a.m. Sept. 2, 2014 - Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 7:31 a.m. Aug. 19, 2014 - Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 6:01 a.m. Aug. 11, 2014 - Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial 5:04 a.m. Aug. 8, 2014 - Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month 6:01 a.m. Aug. 4, 2014 - Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers 6:01 a.m. July 14, 2014 - Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 6:00 a.m. July 7, 2014 - Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 6:01 a.m. June 23, 2014 - Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6:01 a.m. June 16, 2014 - Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol 6:02 a.m. June 2, 2014 - Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities 6:02 a.m. May 27, 2014 - Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market 6:01 a.m. May 19, 2014 - Marketwire
Cellceutix Confident in Its Formidable Antibiotic Arsenal 6:01 a.m. May 12, 2014 - Marketwire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Venture Together's Work Spotlights Inclusion Legacy

Updated Category News Views 5

Hey, if there's one thing that gets my wheels turning, it's a community story that cuts straight to the heart, much like Venture Together's journey. They’ve been at the game for 57 years—it's the kind of legacy you don’t just stumble upon. Venture's been out in Rockland County crafting a blueprint of inclusion and opportunity—a word they live and breathe every...

Continue Reading
IBM Backs Leena AI: Shaping Enterprise Automation

Updated Category News Views 10

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...

Continue Reading
ARPwave Therapy: A Game Changer For Patient Recovery

Updated Category News Views 4

New Insights in Recovery with ARPwave Therapy Getting stuck in a rehab rut is not uncommon. That's where ARPwave therapy steps in, taking an innovative approach to healing by focusing on the nervous system's role in recovery. Props to Jeff Kessler from Maximum Health Physical Therapy for shedding light on this game-changing method during an insightful piece in...

Continue Reading
Food Emulsifiers Market Set for Significant Growth

Updated Category News Views 7

Market Potential: Scratching the Surface Who would have thought that a tiny ingredient like food emulsifiers would hold such massive sway in the food industry? Well, here we are, peering into a future where the global food emulsifiers market could skyrocket to a whopping USD 5.07 billion by 2035. That's right, these unsung heroes of the food world are shaking things up,...

Continue Reading
Ardelyx Investors Face Lawsuit Over Misleading Claims

Updated Category News Views 6

Investors Land in Hot Water with Ardelyx Alright, folks, here we go again. New York's courtroom dramas are in full swing with Ardelyx, Inc. at center stage, and not in a good way. The DJS Law Group has rallied the troops, reminding investors caught in the storm of a class action lawsuit. Specifically, it's all about alleged violations of the Securities Exchange Act of...

Continue Reading
PMET’s Shaakichiuwaanaan Drilling Hits 30,000m Milestone

Updated Category News Views 6

Drilling Deep: PMET's Quest for Mineral Riches You’d be hard-pressed to find another player pushing dirt as fervently as PMET Resources right now. They’ve got their hooks deep into Shaakichiuwaanaan in Quebec—and with over 30,000 meters of drilling chalked up from their elbow grease this year, you better believe it’s shaping up to be a geologist’s dream or a...

Continue Reading
Volkswagen Leads Charge in AI-Driven AV Development

Updated Category News Views 3

Volkswagen's Bold Move into AI for AVs Volkswagen's really cranking the gears on the autonomous vehicle (AV) scene. They’re weaving AI into the mix like no tomorrow. What’s cooking here is their new data flywheel driven by Porsche and partnerships with heavy hitters like NVIDIA and Microsoft. The move aims to cut back on endless test drives and push AV development...

Continue Reading
SINBON's Role in Sustainable Tech Showcase at 2026 Fairs

Updated Category News Views 6

Get this: What do hospitals, charging stations, and data centers have in common? Well, they all rely on data and power connections that are largely invisible but absolutely fundamental to keeping the gears of modern life grinding. SINBON Electronics is stepping up at electronica and SPS 2026, showing how their nifty gadgets transform mundane wires into the beating heart...

Continue Reading
Kenneth Spells: Championing Education Leadership in 2026

Updated Category News Views 1

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

Continue Reading
FAA Greenlights Boeing’s 737-10: What’s at Stake?

Updated Category News Views 7

Breaking New Ground: Boeing 737-10 Certified Well, the folks at Boeing must be popping champagne, because the U.S. Federal Aviation Administration (FAA) just handed them the golden ticket: certification for the brand spankin' new Boeing 737-10. This ain't your average paper-pushing approval. We're talking nearly 1,000 test flights and what seems like a mountain of safety...

Continue Reading

Top 5 Most Recently Viewed Articles

Western Exploration Achieves 94.8% Gold Recovery in Testing

Updated Category News Views 61

Western Exploration Achieves Promising Metallurgical Results Western Exploration Inc. (OTCQX: WEXPF) is thrilled to share the favorable outcomes from recent metallurgical testing of the Aura Project, specifically focusing on the Gravel Creek deposit. The latest tests have revealed exceptional results, notably a gold recovery rate of 94.8% in a combined gravity and...

Continue Reading
PolyPid's D-PLEX100 Demonstrates Efficacy in Surgical Trials

Updated Category News Views 105

PolyPid's D-PLEX100 Shines in Recent Clinical Trials PolyPid Ltd. (NASDAQ: PYPD), a notable player in the biopharma sector, has recently reported promising findings from the Phase 3 SHIELD I trial for its innovative drug D-PLEX100. This local prolonged-release doxycycline formulation is designed specifically for preventing surgical site infections (SSIs) during abdominal...

Continue Reading
Digital Identity Solutions Market Expected to Reach $133.19 Billion

Updated Category News Views 71

Overview of the Digital Identity Solutions Market The Digital Identity Solutions Market is experiencing significant growth, with estimates suggesting it will expand from USD 42.12 billion in 2024 to a remarkable USD 133.19 billion by 2030. This surge represents a Compound Annual Growth Rate (CAGR) of 21.2%, reflecting the increasing importance of digital identity in our...

Continue Reading
Air T Inc. Expands Fleet: Major Acquisition and Financing Update

Updated Category News Views 104

Air T Inc. Secures Funding for Fleet Expansion Air T Inc. (NASDAQ:AIRT), recognized for its air courier services, is making waves with a significant agreement that enhances its asset portfolio. Through its subsidiary, CASP Leasing I, LLC, the company has successfully purchased two aircraft: an Airbus A320 and an Airbus A321. This impressive deal totals over $18 million...

Continue Reading
Omnix Medical Raises $25 Million to Advance Antimicrobials Development

Updated Category News Views 252

Omnix Medical Secures Significant Funding for Growth Omnix Medical, a pioneering biopharmaceutical company, has successfully raised $25 million in a Series C funding round. This financial milestone comes as a result of a collaboration between existing stakeholders and new investors, a move that underscores the growing need for innovative anti-infective solutions in the...

Continue Reading